查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984214

罕見疾病診斷市場：按檢測類型、技術、疾病類型和最終用戶分類的全球市場預測 – 2026-2032 年

Rare Disease Diagnostics Market by Test type, Technology, Disease Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，罕見疾病診斷市場價值將達到 30.2 億美元，到 2026 年將成長至 33.2 億美元，到 2032 年將達到 60.5 億美元，複合年成長率為 10.40%。

主要市場統計數據
基準年 2025 30.2億美元
預計年份：2026年 33.2億美元
預測年份：2032年 60.5億美元
複合年成長率 (%) 10.40%

引言：強調精準罕見疾病診斷在改善患者預後和塑造未來醫療保健策略方面發揮的關鍵作用。

罕見疾病的診斷是現代醫學中最具挑戰性但也最有意義的領域之一，它需要精準、靈活和協作。這些疾病的症狀往往不明顯或不典型，很容易被常規診斷方法忽略。因此，及時準確地識別這些疾病不僅對於啟動改變生活的治療至關重要，而且對於減輕患者及其家庭的情緒和經濟負擔也至關重要。

分析改變罕見疾病診斷方法和縮短準確檢測時間的變革性技術和監管變化。

罕見疾病診斷領域正經歷著翻天覆地的變革，這主要得益於技術突破的整合和法規結構的不斷改進。實驗室服務正從單基因檢測轉向整合基因組學、蛋白質組學和代謝體學資料流的綜合性多組體學平台。這種轉變使臨床醫生能夠超越症狀評估，進行分子層面的診斷，從而指導標靶治療。

評估 2025 年美國關稅變化對罕見疾病診斷供應鏈和成本結構的影響。

美國2025年實施的關稅調整對罕見疾病診斷的整個供應鏈產生了顯著的連鎖反應，影響了成本結構和策略採購決策。關鍵試劑、客製化檢測套組和專用設備的進口關稅，進一步增加了製造商和檢查室在努力維持服務價格合理性和營運柔軟性的困難。

我們將透過按測試類型、技術、疾病類型和最終用戶群體進行細分來挖掘見解，並推動罕見疾病診斷的策略重點。

從多個細分觀點分析罕見疾病診斷市場，有助於釐清當前趨勢和新興機會。從生化、遺傳、組織病理學、免疫和分子生物學等不同診斷方法來看，每種方法都針對不同的臨床需求。生化檢測仍是代謝性疾病的初步篩檢手段，而標靶基因檢測則用於單基因疾病的最終診斷。組織病理學評估在某些腫瘤和免疫性疾病中仍然至關重要，免疫檢測則能快速揭示自體免疫特徵。分子技術展現出高靈敏度和特異性，尤其適用於需要多重檢測的疾病。

為了發現罕見疾病診斷領域的成長機會，我們將分析美洲、歐洲、中東和非洲以及亞太地區的區域趨勢。

了解區域趨勢對於制定能夠發揮本地優勢並應對獨特挑戰的策略至關重要。在美洲，先進的醫療基礎設施、健全的保險報銷體系和雄厚的資本市場為尖端診斷技術的快速應用提供了支援。學術機構和私人企業之間的合作網路進一步加速了轉化研究和臨床檢驗。

我們確定了在罕見疾病診斷領域塑造創新夥伴關係和競爭策略的主要企業。

一群開拓型企業正透過對研發的策略性投資、全球擴張和合作項目，重塑罕見疾病診斷生態系統。產業領導企業正在拓展產品系列，建構整合平台，整合高解析度檢體、自動化樣本處理和先進的生物資訊技術。這些綜合解決方案能夠簡化檢查室工作流程，並以前所未有的速度記錄具有臨床應用價值的見解。

為產業領導者提供切實可行的建議，以加強合作、利用新技術並最佳化罕見疾病診斷結果。

致力於加速罕見疾病診斷進展的產業領導者應採取多管齊下的策略，並專注於合作、技術應用和相關人員參與。與學術機構、病患權益組織和政府機構建立跨部門合作關係，可以整合分散的專業知識，並促進標準化通訊協定達成共識。

詳細的調查方法概述了資料收集和分析框架以及檢驗過程，這些框架和過程有助於深入了解罕見疾病診斷。

本研究採用一套全面的調查方法，旨在確保研究的嚴謹性、透明度和可操作性。主要數據是透過對診斷實驗室、醫院系統、監管機構和患者權益倡導團體的基層專業人員進行深度訪談收集的。這些訪談提供了觀點，包括未滿足的臨床需求、技術應用挑戰和監管的考量。

一個令人信服的結論，總結了核心發現、產業影響和策略挑戰，用於提高罕見疾病診斷能力。

總而言之，罕見疾病診斷的發展得益於先進技術、不斷完善的監管體係以及協作生態系統，使其處於科學創新與病患福祉的交匯點。細分市場分析揭示了具體的成長路徑，而區域性洞察則強調了利用基礎設施優勢並解決特定障礙的在地化策略的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：罕見疾病診斷市場：依檢測類型分類

  • 生物化學檢驗
  • 基因檢測
  • 組織病理學檢查
  • 免疫學檢測
  • 分子檢測

第9章：罕見疾病診斷市場：依技術分類

  • 螢光原位雜合反應（FISH）
  • 質譜分析
  • 下一代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 桑格定序
  • 全EXOME定序
  • 全基因組定序

第10章：罕見疾病診斷市場：依疾病類型分類

  • 心血管疾病
  • 血液疾病
  • 免疫系統疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤性疾病
  • 呼吸系統疾病

第11章 罕見疾病診斷市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院和診所
  • 實驗室和合約研究組織

第12章：罕見疾病診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：罕見疾病診斷市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 罕見疾病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國罕見疾病診斷市場

第16章：中國罕見疾病診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 23andMe Inc.
  • 3billion, Inc.
  • Agilent Technologies Inc.
  • Ambry Genetics
  • ARCHIMED Life Science GmbH
  • ARUP Laboratories
  • AstraZeneca PLC
  • Azenta Life Sciences
  • Baylor Genetics
  • Bio-Rad Laboratories
  • Caris Life Sciences
  • Centogene AG
  • CENTOGENE NV
  • Eurofins Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • MedGenome Labs Ltd
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Travere Therapeutics Inc.
Product Code: MRR-5C6F41F5B034

The Rare Disease Diagnostics Market was valued at USD 3.02 billion in 2025 and is projected to grow to USD 3.32 billion in 2026, with a CAGR of 10.40%, reaching USD 6.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.02 billion
Estimated Year [2026] USD 3.32 billion
Forecast Year [2032] USD 6.05 billion
CAGR (%) 10.40%

Introduction Highlighting the Critical Role of Precise Rare Disease Diagnostics in Improving Patient Outcomes and Shaping Future Healthcare Strategies

Rare disease diagnostics represent one of the most challenging yet rewarding frontiers in modern healthcare, demanding precision, agility, and collaboration. These conditions often present with subtle or atypical symptoms that can elude standard diagnostic pathways. As such, timely and accurate identification is essential not only for initiating life-altering treatment but also for alleviating the emotional and financial burden experienced by patients and their families.

Over the past decade, advances in both laboratory science and digital technologies have transformed our ability to detect and characterize rare conditions. Next-generation sequencing and advanced imaging modalities now offer unprecedented resolution and throughput, while integrated data platforms facilitate deeper insights into genotype-phenotype correlations. In parallel, patient registries and real-world evidence networks fuel longitudinal studies that validate diagnostic algorithms and enhance our understanding of natural histories.

Looking ahead, the importance of rare disease diagnostics will only intensify as personalized medicine gains traction. Precision-driven approaches require not just isolated tests but cohesive diagnostic ecosystems that integrate modular platforms with artificial intelligence and machine learning to refine clinical decision support. These convergent trends underscore the critical role of diagnostics in shaping the future of healthcare strategy and underscore the urgent need for stakeholders to align around a common vision for innovation, efficiency, and patient impact.

Analyzing the Transformative Technological and Regulatory Shifts Redefining Rare Disease Diagnostic Approaches and Accelerating Time to Accurate Detection

The landscape of rare disease diagnostics is undergoing a profound metamorphosis driven by converging technological breakthroughs and evolving regulatory frameworks. Laboratories are transitioning from single-gene assays to comprehensive multi-omics platforms that combine genomic, proteomic, and metabolomic data streams. This shift enables clinicians to move beyond symptomatic assessments and toward molecularly informed diagnoses that can be linked to targeted therapies.

Simultaneously, regulatory agencies are streamlining pathways for breakthrough diagnostics, offering expedited review processes and adaptive protocols that prioritize rapid patient access. Harmonization efforts across jurisdictions are reducing duplicative documentation requirements, fostering global trials, and encouraging collaborative validation studies. As a result, diagnostic developers can navigate complex regulatory environments with greater predictability and speed.

Digital health innovations are further amplifying these transformative shifts. Cloud-based bioinformatics pipelines, decentralized clinical trial models, and telepathology solutions break down geographical barriers, enabling expert interpretation of complex rare disease profiles irrespective of patient location. Collectively, these trends are redefining how diagnostics are designed, validated, and deployed, ultimately accelerating the journey from discovery to clinical application and paving the way for a new era of precision healthcare.

Assessing the Impact of United States Tariff Changes in 2025 on the Landscape of Rare Disease Diagnostics Supply Chains and Cost Structures

The implementation of revised United States tariffs in 2025 has generated notable reverberations throughout the rare disease diagnostics supply chain, influencing both cost structures and strategic sourcing decisions. Import duties on key reagents, custom test kits, and specialized instrumentation have introduced additional layers of complexity for manufacturers and laboratories striving to maintain service affordability and operational flexibility.

In response, organizations are reevaluating supplier portfolios, seeking to diversify procurement channels and establish regional manufacturing hubs that mitigate exposure to fluctuating tariff schedules. Some diagnostic developers have accelerated partnerships with domestic component producers to secure preferential trade classifications and optimize landed costs. Meanwhile, distributors are renegotiating supply contracts to incorporate tariff escalation clauses, protecting margins while preserving service continuity for end users.

Despite the initial cost pressures, these adjustments have also spurred innovation in reagent formulation and assay consolidation. By engineering multi-analyte platforms that maximize throughput from a single sample input, laboratories can offset incremental duties through enhanced efficiency gains. Moreover, the tariff environment has underscored the strategic importance of proactive policy engagement and trade advocacy, empowering stakeholders to shape future tariff reviews and ensure sustainable access to cutting-edge diagnostic technologies.

Unveiling Insights from Test Type Technology Disease Type and End-User Segmentations to Drive Strategic Priorities in Rare Disease Diagnostics

Differentiating the rare disease diagnostics market through multiple segmentation lenses provides clarity around both current dynamics and emerging opportunities. When viewed through the prism of test type-which encompasses biochemical, genetic, histopathological, immunological, and molecular approaches-it becomes evident that each modality addresses distinct clinical imperatives. Biochemical assays continue to serve as frontline screens for metabolic disorders, while targeted genetic tests offer definitive confirmation of monogenic conditions. Histopathological evaluations remain indispensable for certain oncological and immunological disorders, and immunoassays provide rapid insights into autoimmune profiles. Molecular techniques deliver high sensitivity and specificity, especially for conditions requiring multiplexed detection.

Examining the market by technology-ranging from fluorescence in situ hybridization and mass spectrometry to advanced sequencing applications like next-generation, Sanger, whole exome, and whole genome sequencing-reveals an accelerating shift toward high-throughput platforms. These technologies facilitate comprehensive variant calling and enable the discovery of novel biomarkers.

Segmenting by disease type, from cardiovascular and neurological disorders to hematological, immunological, metabolic, oncological, and respiratory conditions, highlights the differential adoption rates and unmet needs within each therapeutic area. Furthermore, analyzing end-user categories-including diagnostic laboratories, hospitals and clinics, and research laboratories and contract research organizations-uncovers varying levels of investment in specialized instrumentation and data analytics capabilities. Together, these segmentation insights illuminate targeted pathways for market entry, resource allocation, and technology deployment.

Exploring Regional Dynamics across the Americas Europe Middle East Africa and Asia Pacific to Identify Growth Opportunities in Rare Disease Diagnostics

Understanding regional dynamics is essential for tailoring strategies that harness local strengths and address unique challenges. In the Americas, advanced healthcare infrastructure, robust reimbursement frameworks, and deep capital markets support rapid adoption of cutting-edge diagnostics. Collaborative networks between academic centers and commercial entities further accelerate translational research and clinical validation.

In Europe, Middle East and Africa, diverse regulatory landscapes coexist with ambitious initiatives aimed at harmonizing diagnostic standards across national borders. Pan-regional consortia facilitate shared access to biobanks and patient registries, while public-private partnerships have emerged to fund innovative assay development. Conversely, certain markets within the Middle East and Africa face infrastructure and training constraints that require targeted capacity-building investments.

Across Asia Pacific, government-led programs are driving domestic manufacturing of diagnostic reagents and instruments, complemented by widespread adoption of digital health solutions. Telemedicine platforms and remote interpretation services are bridging gaps in specialist availability, particularly in emerging markets. Strategic alliances between local companies and global technology providers are expanding the reach of advanced testing capabilities, while at the same time fostering regulatory knowledge transfer and workforce development.

Identifying Key Industry Players Shaping Innovation Partnerships and Competitive Strategies within the Rare Disease Diagnostics Sector

A cadre of pioneering companies is shaping the rare disease diagnostics ecosystem through strategic investments in research and development, global expansion, and collaborative ventures. Industry leaders are extending their product portfolios to encompass integrated platforms that combine high-resolution sequencing with automated sample processing and advanced bioinformatics. These holistic solutions streamline laboratory workflows while delivering clinically actionable insights with unprecedented speed.

Emerging players are carving out niches by focusing on bespoke assay development for ultra-rare conditions or leveraging artificial intelligence to interpret complex genomic datasets. Partnerships between diagnostic innovators and pharmaceutical firms are enabling companion diagnostic programs that align test development with therapeutic pipelines. Meanwhile, alliances with academic institutions and patient advocacy groups are fueling co-creation models that ensure diagnostic designs resonate with real-world clinical needs.

Competitive differentiation is increasingly driven by vertical integration, whereby stakeholders control multiple stages of the value chain-from reagent synthesis through data analytics and result interpretation. As a result, the most successful organizations are those that can orchestrate cross-functional teams to deliver end-to-end diagnostic services, fostering sustained leadership in the rapidly evolving rare disease diagnostics sector.

Actionable Recommendations for Industry Leaders to Enhance Collaboration Leverage Emerging Technologies and Optimize Rare Disease Diagnostic Outcomes

Industry leaders seeking to accelerate progress in rare disease diagnostics should embrace a multifaceted strategy focused on collaboration, technology adoption, and stakeholder engagement. Establishing cross-sector alliances with academic centers, patient advocacy organizations, and government agencies will unify fragmented expertise and drive consensus on standardized protocols.

Investing in modular, scalable platforms that accommodate both targeted panels and broad-spectrum analyses will ensure flexibility to address diverse clinical scenarios. Simultaneously, integrating artificial intelligence and machine learning into diagnostic pipelines can optimize data interpretation, reduce turnaround times, and enhance diagnostic confidence.

Engaging proactively with payers and regulatory bodies through value demonstration studies and real-world evidence generation will facilitate favorable reimbursement and approval pathways. Strengthening supply chain resilience by diversifying suppliers and building regional manufacturing capabilities can mitigate the impact of trade fluctuations. Finally, cultivating a patient-centric approach-incorporating patient feedback loops and transparent communication-will foster trust and improve uptake of novel diagnostic solutions.

Detailed Research Methodology Demonstrating Data Collection Analytical Frameworks and Validation Processes Underpinning Rare Disease Diagnostics Insights

This research integrates a comprehensive methodology designed to ensure rigor, transparency, and actionable insight. Primary data was collected through in-depth interviews with leading experts across diagnostic laboratories, hospital systems, regulatory agencies, and patient advocacy groups. These conversations provided nuanced perspectives on unmet clinical needs, technology adoption challenges, and regulatory considerations.

Secondary research encompassed an extensive review of peer-reviewed literature, clinical trial registries, patent filings, and governmental policy documents to validate emerging trends and technological breakthroughs. Publicly available financial reports and corporate disclosures were analyzed to track strategic investments, partnerships, and market entry activities.

A structured analytical framework was applied to triangulate qualitative insights with quantitative data, facilitating a balanced evaluation of market dynamics. Key findings underwent peer review by an internal advisory board, ensuring methodological consistency and eliminating bias. The resulting report offers a robust foundation for strategic decision-making, combining empirical evidence with expert interpretation.

Compelling Conclusion Summarizing Core Insights Industry Implications and Strategic Imperatives for Advancing Rare Disease Diagnostic Capabilities

In summary, rare disease diagnostics stands at the nexus of scientific innovation and patient impact, driven by advanced technologies, regulatory evolution, and collaborative ecosystems. Segmentation analysis reveals targeted pathways for growth, while regional insights underscore the importance of localized strategies that leverage infrastructure strengths and address specific barriers.

The recalibration of supply chains in response to tariff adjustments highlights both the vulnerabilities and the resilience of the diagnostics ecosystem. Industry leaders and emerging players alike must adopt agile business models that integrate scalable platforms, artificial intelligence, and patient-centric design to maintain a competitive edge.

By implementing the actionable recommendations outlined herein-fostering cross-sector collaborations, engaging proactively with stakeholders, and investing in modular technologies-organizations can enhance diagnostic precision, reduce time to diagnosis, and ultimately transform the patient journey. The collective pursuit of these strategic imperatives will accelerate the realization of a truly precision-driven era in rare disease diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rare Disease Diagnostics Market, by Test type

  • 8.1. Biochemical Tests
  • 8.2. Genetic Tests
  • 8.3. Histopathological Tests
  • 8.4. Immunological Tests
  • 8.5. Molecular Tests

9. Rare Disease Diagnostics Market, by Technology

  • 9.1. Fluorescence in situ Hybridization (FISH)
  • 9.2. Mass Spectrometry
  • 9.3. Next-Generation Sequencing (NGS)
  • 9.4. Polymerase Chain Reaction (PCR)
  • 9.5. Sanger Sequencing
  • 9.6. Whole Exome Sequencing
  • 9.7. Whole Genome Sequencing

10. Rare Disease Diagnostics Market, by Disease Type

  • 10.1. Cardiovascular Disorders
  • 10.2. Hematological Disorders
  • 10.3. Immunological Disorders
  • 10.4. Metabolic Disorders
  • 10.5. Neurological Disorders
  • 10.6. Oncological Disorders
  • 10.7. Respiratory Disorders

11. Rare Disease Diagnostics Market, by End-User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals & Clinics
  • 11.3. Research Laboratories & CROs

12. Rare Disease Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rare Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rare Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rare Disease Diagnostics Market

16. China Rare Disease Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 23andMe Inc.
  • 17.6. 3billion, Inc.
  • 17.7. Agilent Technologies Inc.
  • 17.8. Ambry Genetics
  • 17.9. ARCHIMED Life Science GmbH
  • 17.10. ARUP Laboratories
  • 17.11. AstraZeneca PLC
  • 17.12. Azenta Life Sciences
  • 17.13. Baylor Genetics
  • 17.14. Bio-Rad Laboratories
  • 17.15. Caris Life Sciences
  • 17.16. Centogene AG
  • 17.17. CENTOGENE N.V.
  • 17.18. Eurofins Scientific Inc.
  • 17.19. F. Hoffmann-La Roche Ltd.
  • 17.20. Fulgent Genetics, Inc.
  • 17.21. Illumina, Inc.
  • 17.22. Invitae Corporation
  • 17.23. MedGenome Labs Ltd
  • 17.24. Novartis AG
  • 17.25. OPKO Health, Inc.
  • 17.26. Pfizer Inc.
  • 17.27. Quest Diagnostics Incorporated
  • 17.28. Sanofi S.A.
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. Travere Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)